SABINA: global programme to evaluate prescriptions and clinical outcomes related to short-acting β₂-agonist use in asthma

Abstract

As SABA overuse is associated with exacerbations and mortality, GINA no longer recommends SABA only as a preferred reliever in asthma. A consistent pattern of high SABA use from the SABINA programme would indicate a global public health issue. http://bit.ly/33XDrlbCite this article as: Cabrera CS, Nan C, Lindarck N, et al. SABINA: global programme to evaluate prescriptions and clinical outcomes related to short-acting β 2 -agonist use in asthma.

Asthma-Related Health Outcomes Associated with Short-Acting β2-Agonist Inhaler Use: An Observational UK Study as Part of the SABINA Global Program

“…Limited data on the burden of high SABA use and considerable variability in the definition of SABA 'overuse' [17,[43][44][45] have made comparisons with previous studies and regions challenging. In the SABINA program [21], the definition of high SABA use has been standardized across studies, enabling comparison and harmonization of results across geographies. Table 7 continued BDP beclomethasone dipropionate, BTS British Thoracic Society, CI confidence interval, COPD chronic obstructive pulmonary disease, PDC proportion of days covered, ICS inhaled corticosteroids, IMD Index of Multiple Deprivation, IRR incident rate ratio, N/A not applicable, SABA short-acting b 2 -agonists a The model was adjusted by all the variables shown in the table b Low use: 0-2 SABA canisters/year; high use: C 3 SABA canisters/year Emerging data from more than 1 million patients in the SABINA program reveal that high SABA use is also prevalent in other European countries, such as Sweden (30%), Germany (16%), Spain (29%), and Italy (9%), and is found across asthma severities [46].…”

“…To better understand the impact of SABA inhaler use, the SABINA (SABA use IN Asthma) global program was initiated to describe asthma treatment patterns, the extent of SABA inhaler use, and its subsequent impact on asthma-related clinical outcomes [21]. This study (SABINA I) examined prescription patterns and the impact of SABA inhaler use on asthma-related health outcomes in the UK.…”

SABINA: An Overview of Short-Acting β2-Agonist Use in Asthma in European Countries

“…The SABINA program encompasses three main pillars: SABINA I (a retrospective, observational database study with expanded objectives in the UK), SABINA II (a distributed harmonized set of multicountry retrospective observational database studies in Europe and Canada), and SABINA III (a prospectively collected multicountry cross-sectional study in 25 countries). Full details of the SABINA program are described elsewhere [25]. In this study, prescription data generated from the European arms of SABINA-SABINA I (UK) and SABINA II (Italy, Germany, Spain, and Sweden)-were analyzed.…”

“…There are limited data on SABA and ICS prescription trends in European countries, and a pan-European view of potential SABA overuse and relative ICS underuse is lacking. The SABA use IN Asthma (SABINA) program [25] was therefore initiated to describe the global extent of SABA and ICS use in asthma and its clinical consequences. For the purpose of this analysis, which was to understand the current state of asthma reliever prescriptions relative to recent treatment recommendations, we aimed to provide an overview of the similarities and differences in SABA prescription trends only, for individuals with asthma across European countries.…”

“…Study design features in SABINA I and II SABINA I (UK) SABINA II BTS British Thoracic Society, CPRD Clinical Practice Research Datalink, GINA Global Initiative for Asthma, HERA High Efficiency Reliable Access (to data stores), HES Hospital Episode Statistics, ONS Office for National Statistics, SABINA SABA use IN Asthma inhalations[25]. However, in Germany and Spain, one canister was defined as containing 200 inhalations based on a preliminary analysis of the data, which showed that nearly all prescribed SABA canisters contained 200 doses.…”